Form 4: Cullinan Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director David P. Ryan acquires stock options in Cullinan Therapeutics, Inc.
Summary
- On June 26, 2024, David P. Ryan, a director of Cullinan Therapeutics, Inc. (CGEM), acquired 15,806 stock options.
- The options have an exercise price of $16.50.
- The options vest on the earlier of June 26, 2025, or the date of the Issuer's next annual meeting, contingent upon continued service as a director.
- The options expire on June 26, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director generally indicates confidence in the company's future, but it's a routine transaction.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be informative for investors.
Stakeholder Impact
- The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/26/2024 | Date of transaction: Director acquired stock options. |
| 06/26/2025 | Earliest vesting date for the stock options. |
| 06/26/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.